The goal of this review is to highlight the impact of innovative antihyperglycemic treatments on the function and structure of vital organs in animals with experimentally induced T2D, focusing on next-generation agents, such as SGLT-2 inhibitors and GLP-1 agonists, and their effects on organ damage associated with DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.